Lexeo Therapeutics (LXEO) Total Current Liabilities (2022 - 2026)

Lexeo Therapeutics has reported Total Current Liabilities for 5 years, with the latest figure at $14.2 million in Q1 2026.

• Quarterly Total Current Liabilities fell 53.97% year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (down 53.97% YoY) and the FY2025 annual result came in at $16.8 million, down 26.43% from the prior year.
• Total Current Liabilities slipped to $14.2 million in Q1 2026 per LXEO's latest filing, from $16.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $31.6 million in Q2 2025 and troughed at $14.2 million in Q1 2026.
• A 5-year average of $21.3 million and a median of $20.3 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities jumped 67.36% in 2025, then tumbled 53.97% in 2026.
• Over 5 years, Total Current Liabilities stood at $14.3 million in 2022, then gained by 20.14% to $17.2 million in 2023, then soared by 32.53% to $22.8 million in 2024, then dropped by 26.43% to $16.8 million in 2025, then fell by 15.58% to $14.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $14.2 million, $16.8 million, and $17.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.